Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Mol Biol Cell - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Mol Biol Cell - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
Activation of Adrenoceptor Alpha-2 (ADRA2A) Promotes Chemosensitization to Carboplatin in Ovarian Cancer Cell Lines
Curr Issues Mol Biol. 2023 Nov 28;45(12):9566-9578. doi: 10.3390/cimb45120598.ABSTRACTRecurrence of ovarian cancer (OvCa) following surgery and standard carboplatin/paclitaxel first-line therapy signifies poor median progression-free survival (<24 months) in the majority of patients with OvCa. The current study utilized unbiased high-throughput screening (HTS) to evaluate an FDA-approved compound library for drugs that could be repurposed to improve OvCa sensitivity to carboplatin. The initial screen revealed six compounds with agonistic activity for the adrenoceptor alpha-2a (ADRA2A). These findings were validated in m...
Source: Current Issues in Molecular Biology - December 22, 2023 Category: Molecular Biology Authors: Haya Albanna Alesia Gjoni Danielle Robinette Gerardo Rodriguez Lora Djambov Margaret E Olson Peter C Hart Source Type: research
